EiGen Pharma Limited (all stages of manufacturing process)

The drug is prescribed for adjuvant therapy in postmenopausal women with early-stage invasive breast cancer (after 2–3 years of tamoxifen therapy), as well as for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed after the use of antiestrogens.

Dosage form: tablets, film-coated

ATC: L02BG06